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Background
Atopic dermatitis (AD) is known as having an important
influence in the quality of life (Quol) of patients and their
families, even though, the impact of the subcutaneous
specific-allergen immunotherapy (SCIT) in this field has
sparsely been accessed. This project aims to evaluate the
effect of SCIT in the Quol of Brazilian patients with
moderate/severe AD and their families.
Methods
We analyzed 40 patients with diagnosis of moderate/
severe AD based on the SCORAD and allergological
work-up, under follow-up in the Allergy Department of
our Hospital between 2012 to 2014. The cluster SCIT
has been indicated based on the dust mite specific-IgE
(Dermatophagoides pteronyssinus and/or Blomia tropica-
lis) and clinical relevance of these allergens. To access
the quality of life of patients and their families, we used
specific questionnaires previously validated to Brazilian
Portuguese, the Infant’s Dermatitis Quality of Life Index
(IDQoL) and Dermatitis Family Impact Questionnaire
(DFI), and applied before and after 12 months of the
use of SCIT. The Quol index scores were evaluated
from 0 (best index of Quol) to 32 (worse index of Quol).
Results
Of all 40 patients, 50% were women and the mean age
was 12.4 years. The average index score of IDQoL
before the immunotherapy was 13.59 and 7.7 after 12
months of the SCIT (P<0.001). Meanwhile, the average
DFI was 13.54 in the first evaluation and 8.5 in the last
evaluation (P<0.001). A positive correlation was
observed between the severity of AD and IDQoL scores.
The most important factors related to the decrease of
the IDQoL were the improvement of pruritus (from 2.4
index to 0.9), quality of sleep (from 1.6 to 0.9) and feel-
ings for having a cutaneous disease (from 1.3 to 0.7),
the only domain we didn’t find significant difference
was related to the impressions the patients have regard-
ing the ongoing treatment (frequency of hospital visits).
The major important domains of the DFI scores differ-
ences were the quality of the family’s sleep (from 1.0
index to 0.3), leisure (from 1.0 to 0.5) and costs (from
1.8 to 1.3). No significant difference was seen in the
domain regarding the responsibility of the family on
keeping the patient’s treatment.
Conclusions
This study demonstrates that AD severity impaired the
IDQoL as well as the DFI. The SCIT showed to be
effective on increasing the Qol of AD patients and in
their families, decreasing the index of the majority of
both IDQol and IDF domains.
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